ETC
VRTX icon

Exchange Traded Concepts’s Vertex Pharmaceuticals VRTX Stock Holding History

Exchange Traded Concepts’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.2M Buy
13,875
+1,850
+15% +$863K 0.04% 368
2025
Q4 		$5.45M Buy
12,025
+1,874
+18% +$808K 0.04% 393
2025
Q3 		$3.98M Buy
10,151
+7,565
+293% +$3.16M 0.03% 444
2025
Q2 		$1.15M Sell
2,586
-37
-1% -$17.1K 0.01% 634
2025
Q1 		$1.27M Sell
2,623
-322
-11% -$150K 0.02% 484
2024
Q4 		$1.19M Sell
2,945
-13
-0.4% -$6.03K 0.02% 509
2024
Q3 		$1.38M Sell
2,958
-2,355
-44% -$1.13M 0.03% 425
2024
Q2 		$2.49M Sell
5,313
-128
-2% -$55.6K 0.06% 255
2024
Q1 		$2.27M Sell
5,441
-2,318
-30% -$980K 0.06% 278
2023
Q4 		$3.16M Sell
7,759
-1,371
-15% -$506K 0.08% 191
2023
Q3 		$3.17M Buy
9,130
+799
+10% +$279K 0.09% 177
2023
Q2 		$2.93M Sell
8,331
-1,926
-19% -$649K 0.07% 217
2023
Q1 		$3.23M Buy
10,257
+1,761
+21% +$528K 0.09% 159
2022
Q4 		$2.45M Sell
8,496
-2,390
-22% -$728K 0.07% 170
2022
Q3 		$3.15M Sell
10,886
-867
-7% -$249K 0.1% 112
2022
Q2 		$3.31M Sell
11,753
-2,299
-16% -$615K 0.1% 117
2022
Q1 		$3.67M Buy
14,052
+1,942
+16% +$461K 0.07% 147
2021
Q4 		$2.66M Sell
12,110
-3,346
-22% -$651K 0.05% 215
2021
Q3 		$2.8M Sell
15,456
-11,217
-42% -$2.19M 0.07% 198
2021
Q2 		$5.38M Buy
26,673
+15,666
+142% +$3.28M 0.17% 88
2021
Q1 		$2.37M Buy
11,007
+4,132
+60% +$908K 0.09% 183
2020
Q4 		$1.63M Buy
6,875
+4,468
+186% +$1.03M 0.08% 179
2020
Q3 		$655K Buy
2,407
+1,059
+79% +$292K 0.04% 239
2020
Q2 		$391K Buy
1,348
+819
+155% +$222K 0.06% 245
2020
Q1 		$126K Buy
529
+101
+24% +$23.2K 0.07% 240
2019
Q4 		$94K Buy
+428
New +$86.6K 0.02% 205

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Exchange Traded Concepts's VRTX Position: Q1 2026 in Review

Exchange Traded Concepts increased its Vertex Pharmaceuticals (VRTX) stake by 15% in Q1 2026, buying an estimated $863K and bringing the position to 13,875 shares worth $6.2M. The position accounts for 0.04% of the portfolio, ranked #368.

Exchange Traded Concepts first reported a position in VRTX in Q4 2019 and has held it in 26 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Exchange Traded Concepts held 13,875 shares of Vertex Pharmaceuticals worth $6.2M as of Q1 2026.
  • Exchange Traded Concepts bought 1,850 Vertex Pharmaceuticals shares in Q1 2026, an estimated $863K.
  • Vertex Pharmaceuticals made up 0.04% of Exchange Traded Concepts's portfolio in Q1 2026, its #368 holding.
  • Exchange Traded Concepts first reported a position in Vertex Pharmaceuticals in Q4 2019 and has held it in 26 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Exchange Traded Concepts's 13F filing for Q1 2026, filed 15 Apr 2026.